Category: piperidines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.79099-07-3,1-Boc-4-Piperidone,as a common compound, the synthetic route is as follows.

79099-07-3, Cvclopropylmethyl-{l-[2-(lH-indazol-4-yl)-4-morpholin-4-yl-thienor3,2- d1pyrimidin-6-ylmethyl1-piperidin-4-yl}-(2-methoxy-ethyl)-amine (108).Prepared via [l-(2-Chloro-4-mophiholin-4-yl-thieno[3,2-d]pyrimidin-6- ylmethyl)-piperidin-4-yl]-cyclopropylmethyl-(2-methoxy-ethyl)-amine, prepared from cyclopropylmethyl-(2-methoxy-ethyl)-piperidin-4-yl-amine. Amine preparation: l-BOC-4-piperidone (500mg) and 2-methoxyethylamine(218muL) were stirred in MeOH at room temperature. After 16 h, sodium borohydride was added (190mg) carefully. After a further 3 h, the reaction mixture was diluted with DCM, washed with water, dried (MgSO4) and the solvent removed in vacuo to yield 4-(2-methoxy-ethylamino)-piperidine-l-carboxylic acid tert-butyl ester (560mg).A mixture of 4-(2-methoxy-ethylamino)-piperidine-l-carboxylic acid tert- butyl ester (525mg), cyclopropylmethyl bromide (218muL) and potassium carbonate (340mg) was heated to reflux in MeCN for 16 h. After cooling the reaction mixture was diluted with chloroform, washed with brine, dried (MgSO4) and the solvent removed in vacuo to yield 4-[cyclopropylmethyl-(2-methoxy-ethyl)-amino]- piperidine-1-carboxylic acid tert-butyl ester (475mg). Removal of the BOC group with HCl yielded the desired compound, which was isolated as the hydrochloride salt.1H NMR (400MHz, CDCl3): -0.01-0.01 (2H, m), 0.40-0.48 (2H, m), 1.45-1.60 (3H, m), 1.62-1.70 (2H, m), 1.97-2.04 (2H, m), 2.33 (2H, d), 2.52-2.61 (IH, m), 2.67 (2H, t), 2.92-3.00 (2H, m), 3.25 (3H, s), 3.34 (2H, t), 3.71 (2H, s), 3.82 (4H, t), 4.00 (4H, t), 7.22 (IH, s), 7.49 (IH, t), 7.48 (IH, d), 8.28 (IH, d), 8.90 (IH, s), 10.00 (IH, br); MS (ESf) 562 (MH+).; 111 { l-[2-(lH-Indazol-4-ylV4-morpholin-4-yl-thienor3,2-d”|pyrimidin-6-ylmethyl1- piperidin-4-vU-(2-methoxy-ethyl)-(2,2,2-trifluoro-ethyl)-amine. Via [l-(2-Chloro-4-mophiholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-piperidin-4- yl]-(2-methoxy-ethyl)-(2,2,2-trifluoro-ethyl)-amine, prepared from (2-methoxy- ethyl)-piperidin-4-yl-(2,2,2-trifluoro-ethyl)-amine.Amine preparation: l-BOC-4-piperidinone (2.0Og) and 2-methoxyethylamine (872muL) were stirred together in MeOH (2OmL) at room temperature overnight. Sodium borohydride (760mg) was then added portionwise and the reaction mixture was allowed to stir further at ambient temperature. After 16 h, the solvent was removed in vacuo, the residue was diluted with DCM, washed with brine, dried (MgSO4) and the solvent removed in vacuo. The residue was purified using flash chromatography to yield 4-(2-methoxy-ethylamino)-piperidine-l-carboxylic acid tert-butyl ester as a colourless oil (1.69g).To a solution of 4-(2-methoxy-ethylamino)-piperidine-l-carboxylic acid tert- butyl ester (500mg) in DCM (5mL) and triethylamine (540muL) was added trifluoroacetic anhydride (548muL). The reaction mixture was stirred at room temperature overnight, diluted with DCM, washed with brine, dried (MgSO4) and the solvent removed in vacuo. The residue was purified using flash chromatography to yield 4-[(2-methoxy-ethyl)-(2,2,2-trifluoro-acetyl)-amino]-piperidine- 1 -carboxylic acid tert-huy ester as an oil (685mg).To a solution of 4-[(2-methoxy-ethyl)-(2,2,2-trifiuoro-acetyl)-amino]- piperidine-1 -carboxylic acid tert-butyl ester (685mg) in dry THF (7mL) was added borane-methyl sulfide complex (405uL) at O0C under inert atmosphere. The reaction mixture was refluxed for 3 h, and then stirred at room temperature overnight, quenched with MeOH, diluted with DCM, washed with brine, dried (MgSO4) and the solvent removed in vacuo. The residue was purified using flash chromatography to yield 4-[(2-methoxy-ethyl)-(2,2,2-trifluoro-ethyl)-amino]-piperidine-l -carboxylic acid tert-huy ester as an oil (635mg). Treatment of this compound with HCl in DCM/MeOH furnished the desired amine, isolated as the hydrochloride salt. EPO 1H NMR (400MHz, CDCl3) 1.55-1.64 (2H, m), 1.76-1.82 (2H, m), 2.12-2.18 (2H, m), 2.58-2.62 (IH, m), 2.86 (2H, t, J=6.3Hz), 3.03-3.08 (2H, m), 3.20 (2H, q, J=9.4Hz), 3.33 (3H, s), 3.45 (2H, t, J=6.4Hz), 3.84 (2H, s), 4.00 (4H, t, J=5.1Hz), 7.22 (IH, s), 7.49 (IH, t, J=7.2Hz), 7.48 (IH, d, J=8.3Hz), 8.28 (IH, d, J=7.1Hz), 8.90 (IH, s), 10.00 (IH, br); MS (ESI+) 590 (MH+).

As the paragraph descriping shows that 79099-07-3 is playing an increasingly important role.

Reference£º
Patent; PIRAMED LIMITED; WO2006/46031; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

98977-34-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.98977-34-5,1-tert-Butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.

1-(tert-Butyl) 3-ethyl 4-oxopiperidine-1,3-dicarboxylate (10 g, 36.86 mmol) was suspended in EtOH (200 mL) and cooled to 0¡ãC under a nitrogen atmosphere. Sodiumborohydride (0.7 g, 18.43 mmol) was then added portionwise over 15 minutes and the reaction mixture was stirred for 0.5 h at 25¡ãC. The mixture was evaporated to dryness, the residue was partitioned between EtOAc (200 mL) and saturated aqueous sodium bicarbonate solution (200 mL), then the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (200 mL), dried overmagn1-(tert-Butyl) 3-ethyl 4-oxopiperidine-1,3-dicarboxylate (10 g, 36.86 mmol) was suspended in EtOH (200 mL) and cooled to 0¡ãC under a nitrogen atmosphere. Sodiumborohydride (0.7 g, 18.43 mmol) was then added portionwise over 15 minutes and the reaction mixture was stirred for 0.5 h at 25¡ãC. The mixture was evaporated to dryness, the residue was partitioned between EtOAc (200 mL) and saturated aqueous sodium bicarbonate solution (200 mL), then the aqueous layer was washed with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (200 mL), dried overmagnesium sulfate and concentrated. The residue was purified by FCC, eluting with 0-100percent EtOAc in heptane, to afford the title compound (7.26 g, 85percent) as a clear yellow oil.OH (500 MHz, CDC13) 4.32-4.25 (m, 1H), 4.19 (q, J7.12 Hz, 2H), 4.13-3.85 (m, 1H), 3.71(dt, J 13.35, 3.62 Hz, 1H), 3.51-3.34 (m, 1H), 3.21-2.82 (m, 1H), 2.67-2.56 (m, 1H), 1.89-1.76 (m, 1H), 1.73-1.60 (m, 1H), 1.46 (s, 9H), 1.28 (t,J7.17 Hz, 3H).esium sulfate and concentrated. The residue was purified by FCC, eluting with 0-100percent EtOAc in heptane, to afford the title compound (7.26 g, 85percent) as a clear yellow oil.OH (500 MHz, CDC13) 4.32-4.25 (m, 1H), 4.19 (q, J7.12 Hz, 2H), 4.13-3.85 (m, 1H), 3.71(dt, J 13.35, 3.62 Hz, 1H), 3.51-3.34 (m, 1H), 3.21-2.82 (m, 1H), 2.67-2.56 (m, 1H), 1.89-1.76 (m, 1H), 1.73-1.60 (m, 1H), 1.46 (s, 9H), 1.28 (t,J7.17 Hz, 3H).

The synthetic route of 98977-34-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BENTLEY, Jonathan Mark; BROOKINGS, Daniel Christopher; BROWN, Julien Alistair; CAIN, Thomas Paul; CHOVATIA, Praful Tulshi; FOLEY, Anne Marie; GALLIMORE, Ellen Olivia; GLEAVE, Laura Jane; HEIFETZ, Alexander; HORSLEY, Helen Tracey; HUTCHINGS, Martin Clive; JACKSON, Victoria Elizabeth; JOHNSON, James Andrew; JOHNSTONE, Craig; KROEPLIEN, Boris; LECOMTE, Fabien Claude; LEIGH, Deborah; LOWE, Martin Alexander; MADDEN, James; PORTER, John Robert; QUINCEY, Joanna Rachel; REED, Laura Claire; REUBERSON, James Thomas; RICHARDSON, Anthony John; RICHARDSON, Sarah Emily; SELBY, Matthew Duncan; SHAW, Michael Alan; ZHU, Zhaoning; WO2014/9295; (2014); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.161491-24-3,1-tert-Butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.

161491-24-3, A solution of O1-tert-butyl O3-methyl 4-oxopiperidine-1,3-dicarboxylate (1 g, 3.88 mmol) in DMF (100 mL) was cooled to 0¡ã C. followed by portion wise addition of NaH (60percent dispersion of mineral oil, 0.16 g, 3.88 mmol). The resulting mixture was stirred at the same temperature for 15 min followed by addition of MeI (0.7 mL, 11.64 mmol) at 0¡ã C. then stirred at rt for 44 h. After completion of reaction (by TLC), water (100 mL) was added and extracted with EtOAc (3.x.100 mL). The combined organics were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to obtain the product as a yellow oil (0.9 g). MS: 272.12 [M+H]+.

As the paragraph descriping shows that 161491-24-3 is playing an increasingly important role.

Reference£º
Patent; BIOTA EUROPE LTD.; US2012/88750; (2012); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

7149-42-0, (1-Methylpiperidin-4-yl)methanamine is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

7149-42-0, The intermediate 3-cyano-4-(4-methoxy-4-methyl-piperidin-1-yl)-2-oxo-1,2-dihydro-1,7-naphthyridine-6-carboxylic acid (200 mg, 0.58mmol, 1.0eq), was dissolved in anhydrous N, N- dimethylacetamide (2mL), DIPEA (226.3mg, 1.75mmol, 3.0eq) and HATU (333.1mg, 0.88mmol, 1.5eq), was added and stirred at room temperature 0.5 ~ 1h. a solution of (1-methyl-piperidin-4-yl)methanamine (150mg, 1.17mmol, 2.0eq), the reaction at room temperature 1h. LC-MS monitoring starting material still remaining supplemented with (1-methyl-piperidin-4-yl) methanamine (150mg, 1.17mmol, 2.0eq), the reaction was continued 2h, and purified by preparative HPLC (0.1% aqueous trifluoroacetic acid 30:: acetonitrile = 70) to give product (68.8mg, yield: 20.7%).

As the paragraph descriping shows that 7149-42-0 is playing an increasingly important role.

Reference£º
Patent; Nanjing Yaojie Good Health Biological Technology Co., Ltd.; Wu Yongqian; Li Lin; Yang Xiaoju; (118 pag.)CN109575016; (2019); A;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.159635-49-1,tert-Butyl 4-methylenepiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

159635-49-1, m-Chloroperbenzoic acid (1 .14 g, 6.6 mmol) was added to a solution of tert-butyl 4- methylenepiperidine-1-carboxylate (1 g, 5.1 mmol) in CH2CI2(30 ml.) at 0¡ãC. The reaction mixture was stirred for 15 h at rt, diluted with CH2CI2, washed with a saturated aqueous solution of NaHC03and brine, dried (Na2S04), and evaporated to afford 1.1 g of the title compound which was used without further purification. H-NMR (400 MHz, CDCI3) delta ppm 3.74-3.65 (m, 2 H), 3.45-3.38 (m, 2 H), 2.68 (s, 2 H), 1.82-1.75 (m, 2 H), 1.48-1.41 (m, 2 H), 1.46 (s, 9 H).

As the paragraph descriping shows that 159635-49-1 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; FURET, Pascal; GUAGNANO, Vito; HOLZER, Philipp; MAH, Robert; MASUYA, Keiichi; SCHLAPBACH, Achim; STUTZ, Stefan; VAUPEL, Andrea; WO2013/80141; (2013); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

142752-12-3, 1-(4-Aminophenyl)piperidin-4-ol is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 141-{4-fluoro-2-[4-(4-hydroxypiperidin-1-yl)phenylamino]benzyl}-3-(4-fluoro-3-trifluoromethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; hydrochloride; 0.16 g of compound 3.2 was admixed with 0.10 g of 1-(4-aminophenyl)-piperidin-4-ol, 8 mg of palladium(II) acetate, 39 mg of 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene and 0.33 g of cesium carbonate, before 10 ml of dry dioxane were added under an argon atmosphere. The mixture was stirred at 80 C. for 6 h. The cooled reaction mixture was filtered with suction, the filtrate was concentrated under reduced pressure and the residue was purified by chromatography (method [RP1]). The eluates were concentrated, admixed with hydrochloric acid in dioxane and freeze-dried. This afforded 1-{4-fluoro-2-[4-(4-hydroxypiperidin-1-yl)phenylamino]benzyl}-3-(4-fluoro-3-trifluoromethylphenyl)-5,5-dimethyl imidazolidine-2,4-dione as the hydrochloride (14). Molecular weight (free base) 588.21 (C30H29F5N4O3); retention time Rt=3.91 min. [D]; MS (ESI): 589.52 (MH+)., 142752-12-3

The synthetic route of 142752-12-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SANOFI-AVENTIS; US2011/46105; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4842-86-8,Ethyl 3-piperidinecarboxylate hydrochloride,as a common compound, the synthetic route is as follows.

Example 12 5-[(3-Ethoxycarbonyl)piperidyl]-1-(3-ethoxy-4-methoxyphenyl)-1-penten-3-one hydrochloride Compound No. 12 0.387g (2.0mmol) of 3-ethoxycarbonylpiperidine hydrochloride and 0.4g (14mmol) of paraformaldehyde were dissolved in anhydrous ethanol (5ml). The pH value of the solution was adjusted to pH =2-3 with concentrated hydrochloric acid and the reaction mixture was refluxed and stirred for 2hr. After the solid was dissolved, 0.44g (2.0mmol) of 4-(3-ethoxy-4-methoxyphenyl)-3-buten-2-one (prepared as described in preparation 4) was added to the above reaction mixture. The solution was further refluxed and stirred for 11hr. TLC showed the reaction was completed, after staying overnight at room temperature, the precipitated solid was collected by filtration and then recrystallized from 95% ethanol and dried to give 0.26g of crystals, yield: 30.1 %, mp: 158-160C. 1H-NMR deltappm (DMSO-d6): 1.21(t, 3H, J=7.2 Hz, OCH2CH3), 1.33(t, 3H, J=7.2 Hz, COOCH2CH3), 2.26-2.71(brs, 5H, (CH2)2CH), 3.30-3.40(m, 8H, 3NCH2+COCH2), 3.80(s, 3H, OCH3), 4.10 (d, d, 4H, J=7.2 Hz, J=7.2 Hz, COOCH2CH3, OCH2CH3), 6.82(d, 1H, J=16.2Hz =CHCO), 7.02 (d, 1H, J=9.0Hz, ArH), 7.27(d, J=8.1Hz, 1H, ArH), 7.32(s, 1H, ArH), 7.63(d, 1H, J=16.2Hz, CH=). MS (m/z): 389(M+, 15), 344(M+-45, 12), 232(M+-156+H, 45), 316(M+-73, 3).

4842-86-8, 4842-86-8 Ethyl 3-piperidinecarboxylate hydrochloride 12896004, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; EP1783115; (2007); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

276872-89-0, N-Boc-3-Methylenepiperidine is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of N-Boc-3-methylenepyrazdine (0.4 g) and 9-BBN (12 ml) was cooled to 0 C. for 30 min, and then warmed to room temperature for 2 h. Dioxane (20 ml), PdCl2 (0.05 g), K3PO4 (0.32 g) and 4-chloro-2-(4-chlorophenyl)-thieno[2,3-d]pyridzaine-7-carboxylic acid ethyl ester were heated at 90 C. over night. The reaction mixture was cooled, diluted with ethyl acetate and washed with water. The organic layer was washed with brine, dried over anhydrous Na2SO4 and evaporated. The residue was purified by flash chromatography (silica gel, PE_EA=5:10) to obtain 4-(1-Boc-3-piperidinemethy)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylic acid ethyl ester as a solid (0.3 g). 1H-NMR (400 MHz, DMSO), delta 8.90 (s, 1H), 8.03 (m, 2H), 7.63 (m, 2H), 4.54 (m, 2H), 3.73 (s, 2H), 3.32 (m, 2H), 3.28 (m, 1H), 2.82 (m, 2H), 2.09 (s, 1H), 1.78 (s, 1H), 1.64 (s, 1H), 1.44 (m, 3H), 1.39 (s, 1H), 1.32 (s, 9H). MS (EI): 515 (M+), 486, 458, 442, 414, 334, 332, 306, 304, 149, 57.

276872-89-0, 276872-89-0 N-Boc-3-Methylenepiperidine 11252594, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; Wu, Zhanggui; US2009/275585; (2009); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.672883-95-3,(S)-5-Aminopiperidin-2-one hydrochloride,as a common compound, the synthetic route is as follows.,672883-95-3

A mixture of (-S -5-((4-chloro-5-((4-(3-(3-(4-fluoropiperidin-l-yl)propoxy)-2- methylphenyl)-2,3-dihydro-lH-inden-l-yl)oxy)-2-formylphenoxy)methyl)isophthalonitrile (50.0 mg, 0.074 mmol) and (Patent; CHEMOCENTRYX, INC.; LANGE, Christopher; MALATHONG, Viengkham; MALI, Venkat Reddy; MCMAHON, Jeffrey; MCMURTRIE, Darren J.; PUNNA, Sreenivas; ROTH, Howard S.; SINGH, Rajinder; WANG, Yu; YANG, Ju; ZHANG, Penglie; (164 pag.)WO2019/23575; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem